BC Extra | Jan 11, 2013
Financial News

Esanex raises $500,000 from BioCrossroads

Cancer company Esanex Inc. (Indianapolis, Ind.) raised $500,000 from BioCrossroads Indiana Seed Fund II. The funding is part of Esanex's series A round; according to a December SEC filing, the newco has raised $15.5 million...
BioCentury | Mar 21, 2011
Product Development

Safe to move forward vs. Hsp90

Based on recently reported Phase II data, Synta Pharmaceuticals Corp. thinks it has the first Hsp90 inhibitor to have both meaningful cancer activity and a clean safety profile. It plans to start a Phase IIb/III...
BioCentury | Dec 15, 2008
Finance

Ebb & Flow

In good economic times, companies that run into problems can often avoid tough decisions - such as dropping programs or employees, or shutting their doors - by raising money from less savvy investors. Meanwhile, disgruntled investors can...
BC Week In Review | Mar 10, 2008
Company News

Serenex, Pfizer deal

Pfizer will acquire Serenex for an undisclosed sum. The acquisition gives Pfizer SNX-5422 , an oral heat shock protein 90 (Hsp90) inhibitor in Phase I testing to treat solid tumors and hematological malignancies, as well as...
BioCentury | Mar 10, 2008
Strategy

Hsp90 pipline

Hsp90 pipline Hsp90 pipline Selected compounds targeting heat shock protein 90 (Hsp90) in clinical development for cancer Company Product Formulation Indication Status Kosan (NASDAQ:KOSN) Tanespimycin (KOS-953) IV Multiple myeloma (MM), Ph III (MM), breast cancer...
BioCentury | Mar 10, 2008
Finance

Ebb & Flow

Investors lopped off one-third of PDL Biopharma 's value last Wednesday after the company announced late Tuesday that it was taking itself off the auction block after failing to receive any firm offers to purchase...
BioCentury | Mar 10, 2008
Strategy

Focus pays off for Serenex

By acquiring Serenex Inc. for an undisclosed sum, Pfizer Inc. gets one of only two oral heat shock protein 90 inhibitors in the clinic for cancer. As a bonus, the pharma company also gets Serenex's...
BC Extra | Mar 4, 2008
Company News

Pfizer acquiring Serenex

Pfizer (NYSE:PFE) will acquire Serenex (Durham, N.C.) for an undisclosed amount. The acquisition gives Pfizer SNX-5422 , an oral heat shock protein 90 (Hsp90) inhibitor in Phase I to treat solid tumors and hematological malignancies, as...
BC Week In Review | Mar 3, 2008
Clinical News

SNX-5422: Phase I start

This half, Serenex will begin an open-label, U.S. Phase I trial of oral SNX-5422 in 30-50 patients. Serenex Inc. , Durham, N.C.   Product: SNX-5422   Business: Cancer   Molecular target: Heat shock protein 90 (Hsp90)...
BC Week In Review | Jan 21, 2008
Company News

Serenex, CHDI Inc. deal

Not-for-profit foundation CHDI will assess Serenex's small molecule Hsp90 inhibitors as potential therapeutics for Huntington's disease (HD). Serenex will retain all rights to develop and commercialize the molecules. Further terms were not disclosed. Serenex Inc....
Items per page:
1 - 10 of 40
BC Extra | Jan 11, 2013
Financial News

Esanex raises $500,000 from BioCrossroads

Cancer company Esanex Inc. (Indianapolis, Ind.) raised $500,000 from BioCrossroads Indiana Seed Fund II. The funding is part of Esanex's series A round; according to a December SEC filing, the newco has raised $15.5 million...
BioCentury | Mar 21, 2011
Product Development

Safe to move forward vs. Hsp90

Based on recently reported Phase II data, Synta Pharmaceuticals Corp. thinks it has the first Hsp90 inhibitor to have both meaningful cancer activity and a clean safety profile. It plans to start a Phase IIb/III...
BioCentury | Dec 15, 2008
Finance

Ebb & Flow

In good economic times, companies that run into problems can often avoid tough decisions - such as dropping programs or employees, or shutting their doors - by raising money from less savvy investors. Meanwhile, disgruntled investors can...
BC Week In Review | Mar 10, 2008
Company News

Serenex, Pfizer deal

Pfizer will acquire Serenex for an undisclosed sum. The acquisition gives Pfizer SNX-5422 , an oral heat shock protein 90 (Hsp90) inhibitor in Phase I testing to treat solid tumors and hematological malignancies, as well as...
BioCentury | Mar 10, 2008
Strategy

Hsp90 pipline

Hsp90 pipline Hsp90 pipline Selected compounds targeting heat shock protein 90 (Hsp90) in clinical development for cancer Company Product Formulation Indication Status Kosan (NASDAQ:KOSN) Tanespimycin (KOS-953) IV Multiple myeloma (MM), Ph III (MM), breast cancer...
BioCentury | Mar 10, 2008
Finance

Ebb & Flow

Investors lopped off one-third of PDL Biopharma 's value last Wednesday after the company announced late Tuesday that it was taking itself off the auction block after failing to receive any firm offers to purchase...
BioCentury | Mar 10, 2008
Strategy

Focus pays off for Serenex

By acquiring Serenex Inc. for an undisclosed sum, Pfizer Inc. gets one of only two oral heat shock protein 90 inhibitors in the clinic for cancer. As a bonus, the pharma company also gets Serenex's...
BC Extra | Mar 4, 2008
Company News

Pfizer acquiring Serenex

Pfizer (NYSE:PFE) will acquire Serenex (Durham, N.C.) for an undisclosed amount. The acquisition gives Pfizer SNX-5422 , an oral heat shock protein 90 (Hsp90) inhibitor in Phase I to treat solid tumors and hematological malignancies, as...
BC Week In Review | Mar 3, 2008
Clinical News

SNX-5422: Phase I start

This half, Serenex will begin an open-label, U.S. Phase I trial of oral SNX-5422 in 30-50 patients. Serenex Inc. , Durham, N.C.   Product: SNX-5422   Business: Cancer   Molecular target: Heat shock protein 90 (Hsp90)...
BC Week In Review | Jan 21, 2008
Company News

Serenex, CHDI Inc. deal

Not-for-profit foundation CHDI will assess Serenex's small molecule Hsp90 inhibitors as potential therapeutics for Huntington's disease (HD). Serenex will retain all rights to develop and commercialize the molecules. Further terms were not disclosed. Serenex Inc....
Items per page:
1 - 10 of 40